These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 17301098

  • 1. Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model.
    Imamura Y, Yanagihara K, Fukuda Y, Kaneko Y, Seki M, Izumikawa K, Miyazaki Y, Hirakata Y, Sawa T, Wiener-Kronish JP, Kohno S.
    Eur Respir J; 2007 May; 29(5):965-8. PubMed ID: 17301098
    [Abstract] [Full Text] [Related]

  • 2. Therapeutic administration of anti-PcrV F(ab')(2) in sepsis associated with Pseudomonas aeruginosa.
    Shime N, Sawa T, Fujimoto J, Faure K, Allmond LR, Karaca T, Swanson BL, Spack EG, Wiener-Kronish JP.
    J Immunol; 2001 Nov 15; 167(10):5880-6. PubMed ID: 11698464
    [Abstract] [Full Text] [Related]

  • 3. Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa.
    Sawa T, Ito E, Nguyen VH, Haight M.
    Hum Vaccin Immunother; 2014 Nov 15; 10(10):2843-52. PubMed ID: 25483637
    [Abstract] [Full Text] [Related]

  • 4. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV.
    Frank DW, Vallis A, Wiener-Kronish JP, Roy-Burman A, Spack EG, Mullaney BP, Megdoud M, Marks JD, Fritz R, Sawa T.
    J Infect Dis; 2002 Jul 01; 186(1):64-73. PubMed ID: 12089663
    [Abstract] [Full Text] [Related]

  • 5. Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice.
    Moriyama K, Wiener-Kronish JP, Sawa T.
    Microbiol Immunol; 2009 Nov 01; 53(11):587-94. PubMed ID: 19903258
    [Abstract] [Full Text] [Related]

  • 6. PcrV antibody protects multi-drug resistant Pseudomonas aeruginosa induced acute lung injury.
    Wang Q, Li H, Zhou J, Zhong M, Zhu D, Feng N, Liu F, Bai C, Song Y.
    Respir Physiol Neurobiol; 2014 Mar 01; 193():21-8. PubMed ID: 24418353
    [Abstract] [Full Text] [Related]

  • 7. The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa.
    Kinoshita M, Kato H, Yasumoto H, Shimizu M, Hamaoka S, Naito Y, Akiyama K, Moriyama K, Sawa T.
    Hum Vaccin Immunother; 2016 Nov 01; 12(11):2833-2846. PubMed ID: 27454613
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The protective effects of nasal PcrV-CpG oligonucleotide vaccination against Pseudomonas aeruginosa pneumonia.
    Naito Y, Hamaoka S, Kinoshita M, Kainuma A, Shimizu M, Katoh H, Moriyama K, Ishii KJ, Sawa T.
    Microbiol Immunol; 2018 Dec 01; 62(12):774-785. PubMed ID: 30378708
    [Abstract] [Full Text] [Related]

  • 10. Epidemiological analysis of serum anti-Pseudomonas aeruginosa PcrV titers in adults.
    Yasumoto H, Katoh H, Kinoshita M, Shimizu M, Hamaoka S, Akiyama K, Naito Y, Sawa T.
    Microbiol Immunol; 2016 Feb 01; 60(2):114-20. PubMed ID: 26696420
    [Abstract] [Full Text] [Related]

  • 11. A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models.
    Warrener P, Varkey R, Bonnell JC, DiGiandomenico A, Camara M, Cook K, Peng L, Zha J, Chowdury P, Sellman B, Stover CK.
    Antimicrob Agents Chemother; 2014 Aug 01; 58(8):4384-91. PubMed ID: 24841258
    [Abstract] [Full Text] [Related]

  • 12. Anti-PcrV titers in non-cystic fibrosis patients with Pseudomonas aeruginosa respiratory tract infection.
    Nagaoka K, Yamashita Y, Kimura H, Kimura H, Suzuki M, Fukumoto T, Hayasaka K, Yoshida M, Hara T, Maki H, Ohkawa T, Konno S.
    Int J Infect Dis; 2019 Oct 01; 87():54-59. PubMed ID: 31419482
    [Abstract] [Full Text] [Related]

  • 13. Immunization with 3-oxododecanoyl-L-homoserine lactone-r-PcrV conjugate enhances survival of mice against lethal burn infections caused by Pseudomonas aeruginosa.
    Golpasha ID, Mousavi SF, Owlia P, Siadat SD, Irani S.
    Bosn J Basic Med Sci; 2015 May 25; 15(2):15-24. PubMed ID: 26042508
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pseudomonas aeruginosa Bacteremic Patients Exhibit Nonprotective Antibody Titers Against Therapeutic Antibody Targets PcrV and Psl Exopolysaccharide.
    Thaden JT, Keller AE, Shire NJ, Camara MM, Otterson L, Huband M, Guenther CM, Zhao W, Warrener P, Stover CK, Fowler VG, DiGiandomenico A.
    J Infect Dis; 2016 Feb 15; 213(4):640-8. PubMed ID: 26333940
    [Abstract] [Full Text] [Related]

  • 17. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection.
    Milla CE, Chmiel JF, Accurso FJ, VanDevanter DR, Konstan MW, Yarranton G, Geller DE, KB001 Study Group.
    Pediatr Pulmonol; 2014 Jul 15; 49(7):650-8. PubMed ID: 24019259
    [Abstract] [Full Text] [Related]

  • 18. Efficacy comparison of adjuvants in PcrV vaccine against Pseudomonas aeruginosa pneumonia.
    Hamaoka S, Naito Y, Katoh H, Shimizu M, Kinoshita M, Akiyama K, Kainuma A, Moriyama K, Ishii KJ, Sawa T.
    Microbiol Immunol; 2017 Feb 15; 61(2):64-74. PubMed ID: 28370521
    [Abstract] [Full Text] [Related]

  • 19. An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity.
    Baer M, Sawa T, Flynn P, Luehrsen K, Martinez D, Wiener-Kronish JP, Yarranton G, Bebbington C.
    Infect Immun; 2009 Mar 15; 77(3):1083-90. PubMed ID: 19103766
    [Abstract] [Full Text] [Related]

  • 20. In-Silico Analysis and Protective Efficacy of the PcrV Recombinant Vaccine against Pseudomonas Aeruginosa in the Burned and PA-Infected BALB/c Mouse Model.
    Fakoor MH, Owlia P, Mousavi Gargari SL, Sabokbar A.
    Iran J Immunol; 2020 Jun 15; 17(2):121-136. PubMed ID: 32602466
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.